Business Context and Reporting Period
This Form 8-K was filed by Lucid Diagnostics Inc. on March 3, 2022, reporting events occurring on February 25, 2022. The Company, an emerging growth company, announced the completion of an asset acquisition to establish its own CLIA-certified, CAP-accredited clinical laboratory in Lake Forest, CA, to perform its EsoGuard assay. Additionally, the filing reports the resignation of the Chief Medical Officer.
Key Financial Metrics and Transaction Terms
The filing details a material asset purchase agreement (APA) and a management services agreement (MSA) with ResearchDx, Inc. (RDx). Specific financial terms include:
- Total Purchase Price: Up to $6,200,000 for acquired assets.
- Cash Paid at Closing: $1,000,000.
- Contingent Cash Payments: $1,200,000 upon transfer of California/CLIA/CAP approvals; $1,000,000 upon transfer of specific state licenses (MD, NY, PA, RI).
- Earnout Obligation: Up to $3,000,000 payable over 36 months in quarterly installments of $250,000. Payment may be made in cash or common stock (capped at 19.99% of outstanding shares).
- Management Services Fees: Up to $1,800,000 over 36 months ($150,000 quarterly) plus personnel fees at cost.
- Lease Obligation: Base rent of $71,465 per month for the laboratory space.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period, as this is a current report regarding specific events rather than a periodic financial statement.
Material Changes and Operational Shifts
The primary material change is the transition of laboratory operations for the EsoGuard assay from RDx to LucidDx Labs. Previously, RDx performed testing at its own facility; post-transaction, LucidDx Labs will operate the Lake Forest facility. To facilitate this transition, RDx will provide management services for up to three years while LucidDx builds its operational infrastructure. The Company is utilizing available working capital to fund the initial purchase price payments.
Outlook, Risks, and Contingencies
Regulatory Contingency: The APA includes a "clawback" provision. If approval for the transfer of the CLIA certificate, CAP accreditation, and California license is not obtained by December 31, 2022, LucidDx Labs may elect to void the APA and unwind the transactions (excluding personnel fees already paid).
Operational Risk: There is no assurance that the Company can hire personnel or build out infrastructure in a timely manner to operate the laboratory independently.
Termination Risks: If the MSA is terminated by LucidDx Labs for reasons other than "cause," or by mutual agreement, the full unpaid earnout amount becomes immediately due. If the MSA is terminated for cause, payment obligations cease.
Personnel Change: David F. Wurtman, M.D., resigned as Chief Medical Officer effective March 31, 2022. Brian J. deGuzman, M.D., will assume these duties.
Investor Verification Checklist
- Verify the status of regulatory approvals (CLIA, CAP, State licenses) required to trigger the $2.2 million in contingent cash payments.
- Monitor the Company's working capital levels to ensure ability to fund the $1 million closing payment and subsequent quarterly obligations.
- Assess the timeline for hiring and infrastructure build-out to determine if the Company can operate the laboratory before the MSA expires or is terminated.
- Review the potential dilution impact if the $3 million earnout is paid in stock, noting the 19.99% cap on issued shares.
- Confirm the integration of the new Chief Medical Officer and the stability of the medical leadership team.